Posted by Michael Wonder on 17 Oct 2023
Glofitamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
17 October 2023 - NICE has published final evidence based recommendations on the use of glofitamab (Columvi) for the treatment of patients with relapsed or refractory diffuse large B‑cell lymphoma.
Glofitamab is recommended as an option for the treatment of adults with relapsed or refractory diffuse large B‑cell lymphoma after two or more systemic treatments.
